Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px
Organisation › Details

Inovio (Group)

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis C virus. Partners and collaborators include the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. *

 

Period Start 2005-04-04 renamed
  Predecessor Genetronics Biomedical (Group)
Product Industry electroporation technology
     
Region Region San Diego, CA
  Country United States (USA)
  Street 11494 Sorrento Valley Road
  City 92121-1318 San Diego, CA
  Tel +1-858-597-6006
    Address record changed: 2008-12-07
     
Basic data Employees n. a.
  Currency USD
  Annual sales 4,800,000 (revenues, total, consolidated (2007) 2007-12-31)
  Profit -11,200,000 (2007-12-31)
  Cash 10,250,929 (2007-12-31)
     
    * Document for �About Section�: Inovio Pharmaceuticals, Inc.. (9/10/13). "Press Release: Roche and Inovio Pharmaceuticals Partner On Inovio’s Prostate and Hepatitis B Immunotherapy Products". Basel & Blue Bell, PA.
     
   
Record changed: 2018-10-31

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px

More documents for Inovio (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x113px




» top